Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Anushka Bakshi

- PMLiVE

Astellas and Kelonia enter CAR-T cell therapy collaboration worth over $800m

As part of the deal, Xyphos will combine its iGPS system with Kelonia’s ACCEL technology

- PMLiVE

Novartis’ Consentyx granted approval by SMC to treat hidradenitis suppurativa

The drug is available in Scotland on the NHS to treat the chronic inflammatory condition

- PMLiVE

Santhera’s Duchenne muscular dystrophy drug shows promise as long-term treatment

The muscle-wasting disorder is estimated to affect one in every 3,500 male births worldwide

- PMLiVE

Medicxi forms Alys Pharma with six dermatology-focused companies with $100m

Alys will keep its component companies separate to focus on their platforms

- PMLiVE

Key considerations for delivering impactful CME to HCPs

Learn how to drive engagement with HCPs through effective CME programs

Wiley

- PMLiVE

How are we using AI in med comms?

We're proactive and ambitious in our adoption of AI, but open and responsible with our healthcare clients with how we use it.

Wallace Health

- PMLiVE

Creating accessible health content isn’t easy – but it’s worth it

If you’re trying to engage patients, here are the big challenges and even bigger rewards that come with being health literacy aware.

Wallace Health

- PMLiVE

We’re now a B Corp!

PRESS RELEASE: Wallace Health has been certified as B Corporation, a business that pursues purpose as well as profit.

Wallace Health

- PMLiVE

Wallace Health becomes an accredited PIF TICK member

PRESS RELEASE: Wallace Health gains PIF TICK accreditation to become a ‘trusted information creator’

Wallace Health

- PMLiVE

6 content must-dos for 2024

What are the key trends and innovations that will shape the way we create health content in 2024?  Here are the six things the Wallace Health team will be focusing on...

Wallace Health

- PMLiVE

5 ways to engage HCPs in medical education

How to bring credibility, trust and flexibility into your medical education programs

Wiley

- PMLiVE

Sanofi’s investigational frexalimab shows promise in relapsing forms of MS

Results from a mid-stage of the candidate were recently published in the NEJM

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links